Courtney Geer, Derek Harris, Joel Hardy, and J. Michael Charette

Department of Chemistry, Brandon University, Brandon, Manitoba, Canada









Care through Discovery

INTRODUCTION

Bowen-Conradi Syndrome (BCS)

- Ribosome assembly disorder (ribosomopathy)
- Lethal genetic disorder in the Hutterite population
- 1 out of every 355 lives births (1)
- Autosomal recessive disorder (1)
- Due to a missense D86G amino acid change in the Emg1 protein (2)

Emg1 Protein

- Member of the SSU processome in ribosome assembly
- Methylates the 18S rRNA at residue 1191 in *S. cerevisiae*, 1248 in humans (3)
- Ntd 1191 essential to translational fidelity during decoding
- Disease variant may cause issues in translation, leading to changes in the proteome

AIM

- To comparatively analyze the translation of normal and BCS ribosomes
- Through this analysis we can identify translational differences between normal and BCS ribosomes

BACKGROUND




Figure 1. Presentation of Bowen-Conradi Syndrome

- Failure to thrive/grow
- Small size (5.3 kg at 6 years)
- Developmental delay
- Microcephaly
- Micrognathia
- Flexed limbs and digits





Figure 2. Modification site of Emg1

- Residue 1191 on 18S rRNA
- Isomerized from U to Ψ by snR35 (4)
- Methylated by Emg1 (4)
- Acetylated by Tsr3 (4)
- Close proximity to P-site in decoding region
- Critical for translation

METHODS

RiboPuromycylation Assay Grow yeast WT and BCS cells in dextrose

- Treatment with puromycin for incorporation into nascent proteins (5)
- Extract total protein
- SDS-PAGE
- Anti-puromycin western blot
- Compare banding



CONCLUSIONS

- RiboPuromycylation assay compared translational capacity of ribosomes assembled with either WT or BCS Emg1 protein
- Emg1-WT cells show the most intense banding, giving a baseline for normal translational function
- Empty cells show the lightest banding, demonstrating the negative effect of complete depletion of the Emg1 protein
- Emg1-BCS shows an intermediate banding intensity, indicating sub-optimal translation in BCS cells
- Suggests that decreased translational capacity is part of the molecular pathogenesis of BCS
- Proteomic analysis confirms translational changes in BCS

FUTURE DIRECTIONS

Characterize the mechanism of this decrease in translational capacity in BCS:

- Stop-codon read-through?
- Frameshifting?
- Amino acid mis-incorporation?
- Decreased translation rates?
- Decreased initiation?

Further studies using translation reporter plasmids will elucidate the molecular pathology of BCS, which may lead to treatment strategies.

RESULTS

Figure 3. (**A**) Anti-puromycin western blot showing nascent peptides labeled with puromycin. All treatments show similar banding patterns, but different band intensities. Empty shows the lightest banding, Emg1-WT banding is the darkest, and Emg1-BCS shows an intermediate banding intensity. (**B**) Densitometry analysis of the anti-puromycin western blot quantifies the western blot results presented above. BCS cells demonstrate a decreased translational capacity compared to WT cells.

ACKNOWLEDGEMENTS



REFERENCES

(1) Lowry, R. B. et al. Bowen-Conradi syndrome: A clinical and genetic study. *American Journal of Medical Genetics*. 120A, 423–428 (2003).

(2) Armistead, J., et al. Mutation of a gene essential for ribosome biogenesis, EMG1, causes Bowen-Conradi Syndrome. The American Journal of Human Genetics. 84(6), 728-739 (2009).

(3) Armistead, J., et al. Mutation of EMG1 causing Bowen–Conradi syndrome results in reduced cell proliferation rates concomitant with G2/M arrest and 18S rRNA processing delay. BBA Clinical. 1, 33–43 (2014).

(4) Sharma, S. & Lafontaine, D. L. J. 'View From A Bridge': A new perspective on eukaryotic rRNA base modification. *Trends in Biochemical Sciences*. 40, 560–575 (2015).

(5) David, A. et al. Nuclear translation visualized by ribosome-bound nascent chain puromycylation. *Journal of Cell Biology*. 197, 45–57 (2012).



